Key clinical point: More than one-third of real-world patients with psoriatic arthritis (PsA) who were not in minimal disease activity (MDA) at secukinumab initiation achieved MDA after 6 months of initiating secukinumab along with improvement in other patient-reported outcomes.
Major finding: At 6 months, 36.6% of patients not in MDA at secukinumab initiation achieved MDA and 41.2%, 44.4%, 60.7%, and 75.0% of patients with ≥1 tender joint, ≥1 swollen joint, enthesitis, and dactylitis, respectively, at secukinumab initiation achieved symptom resolution along with improvement in pain, fatigue, and other scores.
Study details: Findings are from an analysis of 100 patients with PsA from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry who initiated secukinumab and maintained the treatment at 6-month follow-up visit.
Disclosures: This study was sponsored by CorEvitas, LLC. Three authors declared being employees of CorEvitas. The other authors reported ties with several sources.
Source: Mease PJ et al. Effectiveness of 6-month use of secukinumab in patients with psoriatic arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2022 (Apr 15). Doi: 10.3899/jrheum.211033